Sophie Paczesny
YOU?
Author Swipe
View article: Pharmacodynamic analysis of AGAVE-201 indicates changes in CSF-1R–expressing cells and associated biomarkers potentially contributing to chronic graft-versus-host disease resolution
Pharmacodynamic analysis of AGAVE-201 indicates changes in CSF-1R–expressing cells and associated biomarkers potentially contributing to chronic graft-versus-host disease resolution Open
Introduction: Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and nonrelapse mortality among patients who undergo allogeneic hematopoietic stem cell transplantation. In patients with cGVHD, colony-stimulating factor…
View article: Risk biomarkers of chronic GVHD in children aged 10 years or younger and children/adults older than 10 years
Risk biomarkers of chronic GVHD in children aged 10 years or younger and children/adults older than 10 years Open
Assessment of risk biomarkers of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT) in pediatric patients is lacking. We conducted a prospective study of 318 patients (129 children aged ≤10 …
View article: Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway
Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway Open
Leukemia stem cells (LSCs) are a small yet powerful subset of leukemic cells that possess the ability to self-renew and have a long-term tumorigenic capacity, playing a crucial role in both leukemia development and therapy resistance. Thes…
View article: Cytokines associated with organ manifestations in chronic graft-versus-host disease
Cytokines associated with organ manifestations in chronic graft-versus-host disease Open
Prior studies have identified cytokines associated with the general syndrome of chronic graft-versus-host disease (cGVHD). The goal of this cross-sectional study was to see if these biomarkers were associated with specific organ manifestat…
View article: Developing catchment area data dashboards for cancer centers: A stakeholder-engaged approach
Developing catchment area data dashboards for cancer centers: A stakeholder-engaged approach Open
A catchment area data resource developed through a systematic, stakeholder-driven, and theory-based approach can meet (and surpass) benchmarks for understandability and actionability, and lead to an overall positive response from stakehold…
View article: Developing Catchment Area Data Dashboards for Cancer Centers: A Stakeholder- engaged Approach
Developing Catchment Area Data Dashboards for Cancer Centers: A Stakeholder- engaged Approach Open
Background Data dashboards that can communicate complex and diverse catchment area data effectively can transform cancer prevention and care delivery and strengthen community engagement efforts. Engaging stakeholders in data dashboard deve…
View article: Minnelide suppresses GVHD and enhances survival while maintaining GVT responses
Minnelide suppresses GVHD and enhances survival while maintaining GVT responses Open
Allogeneic hematopoietic stem cell transplantation (aHSCT) can cure patients with otherwise fatal leukemias and lymphomas. However, the benefits of aHSCT are limited by graft-versus-host disease (GVHD). Minnelide, a water-soluble analog of…
View article: Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight Open
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor’s Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important infor…
View article: Early Prognostic Biomarkers of Non-Relapse Mortality in Allogeneic Mismatched Unrelated Hematopoietic Cell Transplantation
Early Prognostic Biomarkers of Non-Relapse Mortality in Allogeneic Mismatched Unrelated Hematopoietic Cell Transplantation Open
Introduction A major challenge in allogeneic hematopoietic cell transplantation (HCT) has been advancing outcomes for individuals lacking a fully matched donor who require a mismatched unrelated donor (MMUD) HCT. Recently, the 15-MMUD stud…
View article: Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)
Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309) Open
Background: Chronic GVHD (cGVHD) occurs in 30-70% of allogeneic hematopoietic cell transplantation patients, and the rate has increased over the past 2 decades. Based on the degree of organ involvement, cGVHD is classified as mild, moderat…
View article: Prophylactic Mitigation of Acute Graft versus Host Disease by Novel 2-(Pyrrolidin-1-ylmethyl)pyrrole-Based Stimulation-2 (ST2) Inhibitors
Prophylactic Mitigation of Acute Graft versus Host Disease by Novel 2-(Pyrrolidin-1-ylmethyl)pyrrole-Based Stimulation-2 (ST2) Inhibitors Open
Hematopoietic cell transplantation (HCT) is a proven and potentially curable therapy for hematological malignancies and inherited hematological disease. The main risk of HCT is the development of graft versus host disease (GVHD) acquired i…
View article: Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death
Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death Open
BACKGROUNDChronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic hematopoietic cell transplantation (HCT). More accurate information regarding the risk of developing cGVHD is required. Bone marrow (BM) grafts con…
View article: A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept
A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept Open
Respiratory inflammation in bronchiolitis obliterans syndrome (BOS) after hematopoietic cell transplantation (HCT) is poorly understood. Clinical criteria for early-stage BOS (stage 0p) often capture HCT recipients without BOS. Measuring r…
View article: Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation
Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation Open
BACKGROUNDCurrently, no laboratory tests exist to stratify for the risk of developing sinusoidal obstruction syndrome (SOS), an early endothelial complication after hematopoietic cell transplantation (HCT). Risk biomarkers of SOS have not …
View article: Obesity-induced inflammation exacerbates clonal hematopoiesis
Obesity-induced inflammation exacerbates clonal hematopoiesis Open
Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis of indeterminate potential (CHIP) is frequent in aging and involves the expansion of mutated hematopoietic stem and progenitor cells (HSC/P…
View article: Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway
Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway Open
Loss-of-function mutations in the DNA methyltransferase 3A (DNMT3A) are seen in a large number of patients with acute myeloid leukemia (AML) with normal cytogenetics and are frequently associated with poor prognosis. DNMT3A mutations are a…
View article: HLA Evolutionary Divergence Does Not Predict Relapse and Survival Following Allogeneic Hematopoietic Stem Cell Transplant for Myeloid and Lymphoid Malignancies
HLA Evolutionary Divergence Does Not Predict Relapse and Survival Following Allogeneic Hematopoietic Stem Cell Transplant for Myeloid and Lymphoid Malignancies Open
The National Kidney Foundation and the US Food and Drug Administration (FDA) convened a symposium in September 2010, bringing together more than 70 experts, including representatives from the FDA, the National Institutes of Health, the Cri…
View article: Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation
Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation Open
PURPOSE Immunopeptidome divergence between mismatched HLA-DP is a determinant of T-cell alloreactivity and clinical tolerability after fully HLA-A, -B, -C, -DRB1, -DQB1 matched unrelated donor hematopoietic cell transplantation (UD-HCT). H…
View article: Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD Open
Chronic graft-versus-host disease (cGvHD) remains a prominent barrier to allogeneic hematopoietic stem cell transplantion as the leading cause of nonrelapse mortality and significant morbidity. Tremendous progress has been achieved in both…
View article: Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities
Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities Open
Acquired aplastic anemia (AA) is caused by autoreactive T cell-mediated destruction of early hematopoietic cells. Somatic loss of human leukocyte antigen (HLA) class I alleles was identified as a mechanism of immune escape in surviving hem…
View article: Combined heterozygosity of FLT3 ITD, TET2, and DNMT3A results in aggressive leukemia
Combined heterozygosity of FLT3 ITD, TET2, and DNMT3A results in aggressive leukemia Open
Heterozygous mutations in FLT3ITD, TET2, and DNMT3A are associated with hematologic malignancies in humans. In patients, cooccurrence of mutations in FLT3ITD combined with TET2 (TF) or FLT3ITD combined with DNMT3A (DF) are frequent. Howeve…
View article: Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes
Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes Open
Patients with severe aplastic anemia (SAA) can have an unrecognized inherited bone marrow failure syndrome (IBMFS) because of phenotypic heterogeneity. We curated germline genetic variants in 104 IBMFS-associated genes from exome sequencin…
View article: Mouse pulmonary interstitial macrophages mediate the pro-tumorigenic effects of IL-9
Mouse pulmonary interstitial macrophages mediate the pro-tumorigenic effects of IL-9 Open
Although IL-9 has potent anti-tumor activity in adoptive cell transfer therapy, some models suggest that it can promote tumor growth. Here, we show that IL-9 signaling is associated with poor outcomes in patients with various forms of lung…